<DOC>
	<DOCNO>NCT02319005</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy revusiran ( ALN-TTRSC ) patient transthyretin ( TTR ) mediate Familial Amyloidotic Cardiomyopathy . Dosing discontinue ; patient followed-up safety .</brief_summary>
	<brief_title>ENDEAVOUR : Phase 3 Multicenter Study Revusiran ( ALN-TTRSC ) Patients With Transthyretin ( TTR ) Mediated Familial Amyloidotic Cardiomyopathy ( FAC )</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloidosis , Familial</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<criteria>Documented TTR mutation Amyloid deposit cardiac noncardiac tissue Medical history heart failure Evidence cardiac involvement echocardiogram Has know primary amyloidosis ( AL ) , leptomeningeal amyloidosis , nonFAC hereditary cardiomyopathy , hypertensive cardiomyopathy , cardiomyopathy due valvular heart disease Has know peripheral vascular disease affect ambulation Has Polyneuropathy Disability score &gt; 2 Has New York Heart Association ( NYHA ) classification IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>FAC</keyword>
	<keyword>Amyloid</keyword>
	<keyword>Transthyretin</keyword>
	<keyword>TTR</keyword>
	<keyword>RNAi therapeutic</keyword>
</DOC>